HIV Drugs May Treat Prostate Cancer and Chronic Fatigue Syndrome

.

HIV Drugs May Treat Prostate Cancer and Chronic Fatigue Syndrome

University of Utah and Emory University/Veterans Affair Medical Center (VA) conducted a research which concluded that retrovirus associated to chronic fatigue syndrome (CFS) and prostate cancer has been found to be present in four drugs that are used to combat HIV.

The research has raised a hope that if it is found that retrovirus XMRV i. e., Xenotropic murine leukemia virus-related virus causes prostate cancer or CFS; the HIV drugs can prove helpful in curing the same.

Dr. Ila R Singh said that the concluded results were a ray of hope for the patients suffering from prostate cancer and CFS.

The researchers will have to look for a better and magnified understanding of the links between HIV and CFS and prostate cancer for developing drugs that can cure them.

In this research, in cultured human breast cancer and prostate cancer cells, 45 drugs treating HIV were tested for their effectiveness against XMRV.

Raltegravir, L-00870812, Zidovudine and Tenofovir disoproxil fumarate were the drugs tested.

Co-investigator Raymond F Schinazi said that the research revealed that drugs inhibited XMRV at lower levels when used together, which in turn indicate that the virus might restrain the virus from replicating and spreading.


Latest News

Ford Shares Drop With Profit Concerns
Dominion LNG Export Project Gets Green Signal from FERC
Second Quarter Shows Fastest Growth of U.S Economy
Stronger Safeguarding Rules for Service Members Against Predatory Lenders
Yahoo Urged to Buy Rival AOL Inc.
Slowing Down of Inflation May Make it Difficult for BOJ to Achieve its Target
B.K. Modi’s CIO Plans to Start Pre-IPO Fund
American Soda makers Promise to Trim Twenty Percent Calories by 2025
Federal Reserve Bank of Dallas has Hired a Search Firm to Find Suitable Replacem
Stricter Rules on Tax Inversion Push Down Stocks of Firms Considering Such Moves
Brazilian President Says Growth in the U.S. Could Result in an Improvement of Br
Anonymous Whistleblower to get $30 Million from SEC